Propofol Infusion Syndrome & Drug Toxicities

Propofol Infusion Syndrome & Drug Toxicities

Pharmacotherapy in the neuro-ICU carries narrow therapeutic indices. Critically ill neurological patients frequently suffer from disrupted blood-brain barriers, fluctuating organ perfusion, altered protein binding, and multi-organ failure. Among pharmacologic emergencies, Propofol Infusion Syndrome ($PRIS$) represents the most notorious and lethal iatrogenic disaster. Rapid identification of PRIS, cefepime neurotoxicity, and hyperthermic toxidromes is vital to prevent fatal multi-organ collapse.

Propofol Infusion Syndrome (PRIS)

Mitochondrial Pathophysiology

PRIS is a toxic mitochondrial myopathy affecting cardiac and skeletal muscle. Propofol impairs cellular energy generation through two distinct mechanisms:

1. Inhibition of Fatty Acid Transport: Propofol inhibits carnitine palmitoyltransferase-1 ($CPT-1$), the rate-limiting outer mitochondrial membrane enzyme responsible for converting long-chain fatty acyl-CoA into acylcarnitine for transport into the mitochondrial matrix. This blocks long-chain fatty acid $\beta$-oxidation, creating an intracellular deficit of acetyl-CoA and causing cellular accumulation of free fatty acids and toxic acylcarnitines.
2. Disruption of the Electron Transport Chain: Propofol directly uncouples oxidative phosphorylation and inhibits Complex I (NADH dehydrogenase), Complex II (succinate dehydrogenase), and Complex IV (cytochrome c oxidase) of the inner mitochondrial electron transport chain ($ETC$).

Mitochondrial Mechanisms of Propofol Infusion Syndrome (PRIS)
[ Cytosol ]
  Long-Chain Fatty Acyl-CoA ──(X CPT-1 Inhibited by Propofol)──X  Matrix Entry Blocked
  Accumulation of Toxic Free Fatty Acids & Acylcarnitines
        │
[ Inner Mitochondrial Membrane ]
  NADH ──[ Complex I (Inhibited) ]──> CoQ ──[ Complex II (Inhibited) ]──> Cyt C ──[ Complex IV (Inhibited) ]──> O2
  Uncoupling of Oxidative Phosphorylation ──> Zero ATP Generation ──> Severe Cellular Energy Failure
        │
[ Cellular Necrosis & Systemic Collapse ]
  ├── Skeletal Muscle: Severe Rhabdomyolysis, CPK > 50,000 U/L, Hyperkalemia, Myoglobinuria, AKI
  ├── Liver: Hepatic Steatosis, Severe Hepatomegaly, Impaired Lactate Clearance
  └── Myocardium: Brugada-like ECG (Coved ST V1-V3), Heart Block, Ventricular Arrhythmias, Cardiogenic Shock

Deprived of fatty acid oxidation—the primary energy source of resting myocardium and skeletal muscle—cells suffer acute bioenergetic failure, loss of membrane potential, intracellular calcium overload, and cellular necrosis.

Major Risk Factors & Priming Triggers

• Dose & Duration: Infusion rates $> 4\text{ to }5\text{ mg/kg/h}$ ($> 67\text{ to }83\text{ }\mu\text{g/kg/min}$) and duration $> 48\text{ hours}$.
• Exogenous Catecholamines & Glucocorticoids: High levels of epinephrine, norepinephrine, and corticosteroids act as priming triggers. Catecholamines stimulate hormone-sensitive lipase, flooding the circulation with free fatty acids that cannot be oxidized, while glucocorticoids exacerbate muscle catabolism.
• Low Carbohydrate Intake: Depletion of glycogen stores forces tissues to rely exclusively on fatty acid oxidation, accelerating bioenergetic collapse.
• Demographics: Young age (pediatric patients have lower glycogen stores and higher fatty acid dependence) and acute neurologic trauma ($TBI$, $SAH$, status epilepticus).

Clinical Presentation & Hallmarks

PRIS typically presents as an unexpected, explosive multi-system deterioration:

• Refractory High-Anion-Gap Metabolic Acidosis: Severe, progressive lactic acidosis refractory to bicarbonate administration, resulting from mitochondrial inhibition and hepatic clearance failure.
• Severe Rhabdomyolysis: Marked elevation of creatine kinase ($CK > 10{,}000\text{ to }> 100{,}000\text{ U/L}$), myoglobinuria ("tea-colored" urine), hyperkalemia, and acute tubular necrosis ($ATN$).
• Hypertriglyceridemia: Plasma triglycerides frequently exceed $400\text{ to }1000\text{ mg/dL}$ due to impaired lipid clearance and continuous lipid emulsion infusion.
• Hepatomegaly & Hepatic Failure: Fatty infiltration of hepatocytes causes rapid liver enlargement and transaminitis.
• Refractory Cardiovascular Collapse: Progressive myocardial failure, profound cardiogenic shock refractory to high-dose inotropes, and electrical instability:
  • Brugada-like ECG Pattern: Coved ST-segment elevation with T-wave inversion in precordial leads $V_1\text{ to }V_3$.
  • Progressive conduction blocks: widening QRS, right bundle branch block ($RBBB$), sinus bradycardia, ventricular tachycardia/fibrillation, and asystole.

Prevention, Surveillance, and Emergency Management

PRIS Surveillance & Emergency Protocol
├── Prevention: Cap infusion at <= 4 mg/kg/h (<= 67 µg/kg/min), avoid infusions > 48 hours
├── Monitoring: Baseline & daily triglycerides, CK, arterial blood gas (lactate), electrolytes (K+)
└── Immediate Emergency Management upon Suspicion:
    ├── 1. INSTANTLY HALT PROPOFOL (switch to ketamine, dexmedetomidine, midazolam)
    ├── 2. Hemodynamic Resuscitation: Milrinone/glucagon, pacing, VA-ECMO cannulation
    └── 3. Extracorporeal Elimination: High-flux CRRT/hemodialysis for K+, lactate, and myoglobin

Other ICU Drug Toxicities

Cefepime Neurotoxicity

Cefepime is a widely prescribed fourth-generation cephalosporin that crosses the blood-brain barrier ($BBB$). It acts as a concentration-dependent competitive antagonist of $GABA_A$ receptors, disinhibiting cortical excitatory pathways.

• Risk Factor: Failure to adjust cefepime doses for reduced glomerular filtration rate in acute kidney injury ($AKI$) or chronic renal failure.
• Clinical Manifestations: Onset typically occurs 2 to 5 days after therapy initiation, presenting with altered mental status, fluctuating encephalopathy, confusion, multifocal myoclonus, asterixis, and non-convulsive status epilepticus ($NCSE$).
• EEG Hallmarks: Characteristic generalized periodic discharges ($GPDs$) with triphasic morphology at $1\text{ to }2\text{ Hz}$, rhythmic delta activity, or continuous sharp-and-slow complexes.
• Treatment: Immediate discontinuation of cefepime. Because cefepime exhibits low plasma protein binding ($20\%$) and renal excretion, emergent hemodialysis rapidly eliminates up to $70\%$ of circulating drug within a single 3-hour session, leading to clinical and electrographic recovery within 24 to 48 hours.

Serotonin Syndrome vs. Neuroleptic Malignant Syndrome (NMS)

Both conditions present as life-threatening hyperthermic syndromes in the neuro-ICU but stem from opposing neurochemical pathways requiring distinct management: